Related Experiment Video
Updated: May 24, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Evaluation of PI3K Levels and miRNA124-5p Expression Levels in Serum Samples from Patients With Lung Cancer
Fatma Tuba Akdeniz1, Orcun Avsar2
1Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Istanbul Okan University, Istanbul, Türkiye.
Background/Aim:
Lung cancers are malignant neoplasms located in the lung tissues. miRNAs are short non-coding RNAs. It is known that miRNA-124 prevents metastasis in lung cancers. The phosphatidylinositol 3-kinases (PI3K) signaling pathway, a basic signaling pathway interconnected with other pathways, is activated during cancer development. This study aimed to compare miRNA-124-5p and PI3K serum levels in patient and control groups.
Materials And Methods:
miRNA isolated from patient and control serum samples were converted into cDNA. miRNA-124-5p expression was determined using Real-Time PCR and a SYBR GREEN kit. PI3K serum level was determined using the Enzyme-Linked Immunosorbent Assay.
Results:
While miRNA-124-5p serum level was statistically significantly lower in the patient group (p>0.02), serum PI3K level was higher in the patient group than in the control group but the difference was not statistically significant (p>0.11).
Conclusion:
Lower serum levels of miRNA-124-5p and high PI3K levels observed in the patient group, compared to the control group, may be associated with a poor disease prognosis.
